welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sulindac/Erlotinib Combo Tested in Patients with Familial Adenomatous Polyposis
A lower duodenal polyp burden was seen after 6 months of treatment with sulindac and erlotinib vs. placebo among patients with familial adenomatous polyposis (FAP), a study published in JAMA reports.
expertly curated content related to this topic
-
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of...This phase II trial studies the side eff...
-
Levels of Rectal Mucosal Polyamines and Prostaglandin E2 Predict Ability of DFMO and Sulindac to Prevent Colorectal ...BACKGROUND & AIMS : Combination of p...
-
Polyposis Syndromeshttp://www.slideshare.net/muzzain1/new-p...
-
Chemoprevention in Familial Adenomatous Polyposis: A review of the Concept of Chemoprevention and the Current Clini...Familial adenomatous polyposis (FAP) pre...
-
Does a Selective Cyclooxygenase-2 Inhibitor (Tiracoxib) Induce Clinically Sufficient Suppression of Adenomas in Pati...BACKGROUND : There have been few placebo...
-
Searchable Interface for Patient Education Information – Familial Adenomatous Polyposis (FAP)Familial Adenomatous Polyposis (FAP) is ...
-
Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) is ...